Rida Fatima, MD.
Dr. Fatima has no financial relationships with companies related to this material.
REVIEW OF: Maji S et al, Psychiatry Res 2024;342:116257
STUDY TYPE: Randomized, double-blind, placebo-controlled clinical trial
Dextromethorphan is best known as an over-the-counter cough suppressant, but it also acts as an NMDA receptor antagonist (like ketamine) and modulates serotonin and norepinephrine. It’s already paired with bupropion in the combo pill Auvelity, where bupropion’s CYP2D6 inhibition prolongs the action of 90 mg of dextromethorphan. This study investigated lower doses of dextromethorphan with SSRIs for early augmentation in mild to moderate MDD.
Researchers randomly assigned 60 adults—about half under 35—to receive either 30 mg/day of dextromethorphan or a placebo for 8 weeks. All had been depressed for about 6–7 weeks and had started SSRIs (the equivalent of 50 mg of sertraline) within 4 weeks. Patients with a history of substance use were excluded. The primary outcome was change in Montgomery–Åsberg Depression Rating Scale (MADRS) score. Secondary measures included response (≥ 50% improvement), remission (MADRS < 7), Clinical Global Impression Scale (CGI) scores, and tolerability.
Patients receiving dextromethorphan showed a significantly greater MADRS reduction, with a large effect size (Cohen’s d = 1.05) and nearly double the response and remission rates of patients receiving placebo. CGI improvements were also significantly better. The treatment was well tolerated, with no serious adverse events. Improvement was most pronounced in those with moderate depression and in patients receiving sertraline; however, the effects of paroxetine and fluoxetine were hard to study given the low sample size.
CARLAT TAKEPlease see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.
© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.